Navigation Links
FDA Approves New Treatment for a Type of Late-Stage Skin Cancer
Date:3/25/2011

SILVER SPRING, Md., March 25, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Yervoy (ipilimumab) to treat patients with late-stage (metastatic) melanoma, the most dangerous type of skin cancer.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Melanoma is the leading cause of death from skin disease. An estimated 68,130 new cases of melanoma were diagnosed in the United States during 2010 and about 8,700 people died from the disease, according to the National Cancer Institute.

"Late-stage melanoma is devastating, with very few treatment options for patients, none of which previously prolonged a patient's life," said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "Yervoy is the first therapy approved by the FDA to clearly demonstrate that patients with metastatic melanoma live longer by taking this treatment."

Yervoy is a monoclonal antibody that blocks a molecule known as cytotoxic T-lymphocyte antigen or CTLA-4. CTLA-4 may play a role in slowing down or turning off the body's immune system, affecting its ability to fight off cancerous cells. Yervoy may work by allowing the body's immune system to recognize, target, and attack cells in melanoma tumors. The drug is administered intravenously.

Yervoy's safety and effectiveness were established in a single international study of 676 patients with melanoma. All patients in the study had stopped responding to other FDA-approved or commonly used treatments for melanoma. In addition, participants had disease that had spread or that could not be surgically removed.

The study was designed to measure overall survival, the length of time from when this treatment started until a patient's death. The randomly assigned patients received Yervoy plus an experimental tumor vaccine called gp100,
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Zostavax Vaccine to Prevent Shingles in Individuals 50 to 59 Years of Age
2. FDA Approves Gadavist for Central Nervous System Scans
3. U.S. FDA Approves Bayers Gadavist™ (Gadobutrol) Injection for MRI of the Central Nervous System
4. FDA Approves Device to Maintain Blood Flow During Artery Bypass Brain Surgery
5. FDA Approves BENLYSTA® for Lupus in Breakthrough for Millions of Sufferers
6. FDA Approves Revised Alphanate® Labeling to Include Reduced Infectivity of an Experimental Model Agent for vCJD
7. UPDATE: FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease
8. FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease
9. FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
10. FDA Approves Edarbi to Treat High Blood Pressure
11. FDA Approves EDARBI (azilsartan medoxomil) for the Treatment of Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Reportlinker.com announces that a ... catalogue: The Market for Medical Devices ... The European, Middle Eastern and African markets represent ... part of its coverage, this study: The Market ... EMEA medical device markets and estimates markets for ...
(Date:8/20/2014)... Aug 20, 2014 Reportlinker.com announces that ... its catalogue: Global Patient Scales Industry ... This report analyzes the worldwide markets for Patient ... Segments: Floor Scales, Infant & Baby Scales, Chair ... separate comprehensive analytics for the US, Canada, Japan, ...
(Date:8/20/2014)... MUMBAI , August 20, 2014 ... owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), ... studies of a novel clinical development candidate, GBR ... discovered and developed by the Glenmark Biologics Research ... . GBR 1302 is based on Glenmark,s ...
Breaking Medicine Technology:The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3
... Inc. (Nasdaq: BNVI ), a pharmaceutical company focused ... health and cancer, today announced that it had received the ... Guidance meeting that took place on November 8, 2010. In ... clinical development plan. "We had a very ...
... U.S.A. Inc., (TRL) announced today that it has entered into ... development of novel protein therapies for autoimmune diseases based on ... Anaphore will generate novel trivalent proteins called Atrimers ... inhibit targets of interest . The partnership will focus ...
Cached Medicine Technology:Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 2Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 3Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 4Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders 2Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders 3
(Date:8/20/2014)... (HealthDay News) -- A group representing U.S. obstetricians is ... shot. According to the American College of Obstetricians ... have upheld the safety and effectiveness of flu vaccination ... and can be particularly dangerous to pregnant women, as ... Dr. Laura Riley, chair of the college,s Immunization Expert ...
(Date:8/20/2014)... Bottom Line: A study in Australia examined patient ... rates (a marker of tumor cell growth) in ... aggressive cancer in patients. , ... in Victoria, Australia, and colleagues. , Background: ... of cell division) has been connected with prognosis ...
(Date:8/20/2014)... Aug. 20, 2014 -- An imaging study of ... found deficits in specific regions of brain white ... in CCS users. , Researchers used diffusuion ... with fractional anisotropy, to investigate the white matter ... in multiple regions of the brain, including the ...
(Date:8/20/2014)... hearts transplanted into baboons survived for more than a ... researchers report. The work is part of efforts ... transplant waiting lists. In this study, scientists transplanted ... genetic engineering and new methods of suppressing the baboons, ... survive for more than a year. The genetic ...
(Date:8/20/2014)... Dennis Thompson HealthDay Reporter ... may help older women avoid a condition that causes a ... postmenopausal women had a 10 percent lower risk of developing ... report in the Aug. 20 issue of the Journal ... this protection against the heart rhythm disorder even if they ...
Breaking Medicine News(10 mins):Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Patient, tumor characteristics for high-mitotic rate melanoma 2Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3
... a study done to evaluate the effect of diseases on ... with HIV // were less likely to get the kind ... a quarter of HIV-positive parents report avoided certain types of ... transmit the disease to their children or pick up infections ...
... People with gum disease are more likely to suffer from ... to heart attack // or stroke shows latest research . ... in the mouths of 657 people who had no history ... carotid artery, used to identify atherosclerosis, was also measured. People ...
... recent study researchers say , cancer patients have a ... clots in the legs or lungs. ,Researchers studied ... blood clot in their legs or lungs. They evaluated ... carrier status of gene mutations. Patients underwent anticoagulant (anti-clotting) ...
... at the fiber intake among kids shows , most small children ... their diets thereby putting them at higher risk for health problems ... a survey, conducted between 1994 and 1996 and in 1998, on ... of 2 and 5. Results showed most kids got what fiber ...
... can have a reduced risk of brain damage and cerebral ... after birth according to a recent study. ,Babies ... during delivery showed signs of being at a high risk ... happen immediately when babies are oxygen-deprived instead, researchers say a ...
... researchers studied comparative energetics of both lean and obese ... Results showed that NEAT -- non-exercise activity thermogenesis , ... Researchers say calories people burn during everyday activities are ... sit, on average, about 150 minutes more each day ...
Cached Medicine News:
... Lipoprint System is a high resolution diagnostic test ... by other methods. The test procedure is simple ... hours. Any abnormal value is clearly flagged. A ... atherogenic, small dense LDL in red and the ...
... is the only control for ... patient synovial fluid samples performed ... is also an aid for ... indicate a pathological condition present ...
... Suitable for use with Leica ... bilirubinometers (pediatric) and all automated ... including Aeroset, AU Series, Cobas, ... These controls contain purified bilirubin ...
... designed for point-of-care dipstick control. Its unique, ... problems and provides maximum portability ideal ... is the addition of creatinine and microalbumin. ... results for hCG for early pregnancy detection ...
Medicine Products: